Liver Cancer Diagnostics Market Analysis to Reach USD 25,995 million by 2032 | Credence Research

NEW YORK - April 1, 2024 - PRLog -- The latest market report published by Credence Research, Inc. The market for liver cancer diagnostics is projected to witness significant growth, with its value expected to surge from USD 11,725.23 million in 2023 to USD 25,995 million by 2032, reflecting a compound annual growth rate of 7.86%.

Liver cancer, one of the most lethal malignancies worldwide, poses a significant health burden globally. Early detection plays a pivotal role in enhancing patient outcomes and survival rates. In recent years, the landscape of liver cancer diagnostics has witnessed remarkable advancements, driven by innovative technologies and evolving diagnostic modalities.

The Liver Cancer Diagnostics Market is experiencing a paradigm shift, propelled by the increasing incidence of liver cancer and the pressing need for accurate and timely diagnosis. According to the World Health Organization (WHO), liver cancer is the fourth leading cause of cancer-related deaths worldwide. Timely detection remains a challenge, as symptoms often manifest at later stages when treatment options are limited.

One of the key drivers of innovation in liver cancer diagnostics is the advent of molecular diagnostics and biomarker-based assays. These technologies enable healthcare professionals to detect liver cancer at its earliest stages by analyzing specific biomarkers indicative of disease progression. Biomarker panels, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and glypican-3 (GPC3), are increasingly utilized for early detection and risk stratification.

Browse the Full Report: https://www.credenceresearch.com/report/liver-cancer-diagnostic-market

Furthermore, advancements in imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound have revolutionized the diagnosis and staging of liver cancer. These imaging techniques provide detailed anatomical information, facilitating accurate tumor localization, characterization, and assessment of vascular involvement.

Liquid biopsy, a non-invasive diagnostic approach, holds immense promise in the early detection and monitoring of liver cancer. By analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs) shed by tumors into the bloodstream, liquid biopsy offers a minimally invasive means of detecting tumor-specific alterations and monitoring treatment response.

Key Players

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Agilent Technologies Inc.
• Bayer AG
• BD (Becton Dickinson and Company)
• Bio-Rad Laboratories Inc.
• GE Healthcare
• Thermo Fisher Scientific Inc.
• Tosoh Corporation
• Illumina Inc.
• Merck KGaA
• PerkinElmer Inc.
• QIAGEN N.V.
• Sysmex Corporation

By Segments:

By Test Type:

• AFP Tests
• LFTs
• Biopsy
• Others

By End User:

• Hospital-associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Rest of World